The Correlation between Deglycosylation of PD-L1 and Gene Mutations and Their Effects on the Prognosis of Patients with Lung Adenocarcinoma

Abstract

Aim: The aim of this study was to define the clinical significance of deglycosylation of PD-L1 and its correlation with EGFR and ALK mutation in lung adenocarcinoma. Methods: Lung adenocarcinoma tissue microarray sections were obtained from Outdo Biotech. We estimated the intensity of both native and deglycosylated PD-L1 signals by a 28-8 antibody. We analyzed the difference in the H-score between tumor and paratumor tissues, as well as that before and after deglycosylation. Correlations between EGFR or ALK status and PD-L1 expression were analyzed. We also evaluated the differences among survival curves. Results: The expression level of PD-L1 in lung adenocarcinoma tissues was significantly higher than that in paratumor tissues (P 0.05). Conclusion: PD-L1 deglycosylation enhances the detection of PD-L1 when utilizing a 28-8 antibody. Moreover, the response to deglycosylation of PD-L1 may predict the survival of certain patients with lung adenocarcinoma. Our research provides a more effective strategy for estimating PD-L1 expression and predicting patient outcomes in lung adenocarcinoma.